Document:

Exhibit 10.1

 

SECURITIES
PURCHASE AGREEMENT

 

THIS SECURITIES
PURCHASE AGREEMENT (the “Agreement”), dated as of March __, 2020, is entered into by and between BioHiTech
Global, Inc., a Delaware corporation, (the “Company”) and each purchaser identified on a signature page of
the Agreement (each a “Purchaser”, and collectively, the “Purchasers”).

 

WITNESSETH:

 

WHEREAS, the
Company and the Purchaser are executing and delivering this Agreement in accordance with and in reliance upon the exemption from
securities registration afforded, inter alia, by Rule 506 under Regulation D (“Regulation D”) as promulgated
by the United States Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the
 “1933 Act”), and/or Section 4(2) of the 1933 Act; and

 

WHEREAS, subject
to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to each Purchaser, and each Purchaser,
severally and not jointly, desires to purchase from the Company for a minimum investment amount of One Hundred Fifteen Thousand
Dollars ($115,000), units (the “Units”) consisting of (i) One Thousand (1,000) shares of the Company’s newly-created
Series F Redeemable. Convertible Preferred Stock, par value $0.0001 per share (the “Series F Shares”) at
the Purchase price of One Hundred Fifteen Dollars ($115.00) per share (the “Stated Value”) (the Certificate of Designation
of Rights and Preferences of the Series F Shares (the “Designation”) is attached as Exhibit A hereto)
and (ii) warrants to purchase Thirteen Thousand Six Hundred Ninety One (13,691) shares of Common Stock (the “Warrants,”
and together with the Units and the Series F Shares, the “Securities”), at an exercise price of $2.30 per share
(the “Exercise Price”) . The form of Warrant is attached as Exhibit B hereto. The Series F
Shares are redeemable by the Company for cash, provided that such cash payment is permissible under the Company’s existing
indebtedness or obligations as more fully set forth in the Designation, or for shares of the Company’s common stock, par
value $0.0001 per share (the “Common Stock”). The Series F Shares will also accrue dividends at the rate of nine
percent (9%) per annum, payable in semi-annual installments of cash, provided such cash payment is permitted, or at the option
of the Purchaser, shares of Common Stock at the Conversion Price. In addition, the Series F Shares, plus any accrued and unpaid
dividends, may be converted into Common Stock at the Conversion Price.

 

WHEREAS, the
Company is offering (the “Offering”) up to a maximum of Twenty-Six (26) Units up to the maximum amount of Three Million
Dollars ($3,000,000) (the “Maximum Offering”). The Company reserves the right, in its sole discretion, to increase
the size of the Offering up to an additional Four Hundred Sixty Dollars ($460,000) without notice to or the approval of the Purchasers.
The Company is offering the Units on a “best efforts” basis and there is no minimum offering amount. The minimum investment
amount the Company will accept is One Hundred Fifteen Thousand Dollars ($115,000), however, the Company reserves the right, in
its sole discretion, to accept fractional amounts.

 

NOW THEREFORE,
in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1.            DEFINITIONS;
AGREEMENT TO PURCHASE.

 

a.           Certain
Definitions. As used herein, each of the following terms has the meaning set forth below, unless the context otherwise
requires:

 

(i)          “Closing
Date” means the date on which a Closing is held.

 

(ii)         “Common
Stock” shall have the meaning ascribed to such term in the Recitals.

 

(iii)        “Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
Stock.

 

    1

     

    

 

(iv)        “Conversion
Price” means the Conversion Price of $2.10 per share of Common Stock, as more fully defined in the Designation.

 

(v)       
  “Dollars” or “$” means United States Dollars.

 

(vi)        “Exchange
Act” means the Securities Exchange Act of 1934, as amended.

 

(vii)       “Exempt
Issuance” means (i) the issuance of Common Stock pursuant to the Company’s existing or future stock option, stock
purchase or bonus plans; (ii) the issuance of Common Stock pursuant to outstanding warrants and the vesting of restricted
stock awards; and (iii) the issuance of shares of Common Stock or Common Stock Equivalents in connection with any merger or
acquisition of securities, businesses, property or other assets or strategic investment (including any joint venture, strategic
alliance, partnership, equipment leasing arrangement or debt financing).

 

(viii)      “Material
Adverse Effect” means a material adverse effect on the business, operations or condition (financial or otherwise), prospects
or results of operation of the Company and its Subsidiaries taken as a whole, in the sole and absolute discretion of the Purchaser,
irrespective of any finding of fault, magnitude of liability (or lack of financial liability) or purported lack of materiality
(it being understood that the mere finding of any such violation is in itself material and adverse). Without limiting the generality
of the foregoing, the occurrence of any of the following, in the sole and absolute discretion of the Purchaser, shall be considered
a Material Adverse Effect: (i) any final money, judgment, writ or warrant of attachment, or similar process (including an
arbitral determination) in excess of One Million ($1,000,000) shall be entered or filed against the Company or any of its Subsidiaries
(including, in any event, products liability claims against the Company or its Subsidiaries), (ii) the suspension or withdrawal
of any governmental authority or permit pertaining to a material amount of the Company’s or any Subsidiary’s products
or services, or (iii) an action by a regulatory agency or governmental body affecting the Common Stock (including, without
limitation, (1) the commencement of any regulatory investigation of which the Company is aware, the suspension of trading
of the Common Stock by the Financial Industry Regulation Authority (“FINRA”), the SEC, Nasdaq, the failure of the Common
Stock to be DTC eligible or the placing of the Common Stock on the DTC “chill list” or (2) the engaging in any
market manipulation or other unlawful or improper trading or other activity by any Affiliate).

 

(ix)         “Person” means any living person or any entity, such as, but not necessarily limited to, a corporation, partnership
or trust.

 

(x)     
     “Purchase Price” means the price that the Purchaser pays for the Securities at the Closing.

 

(xi)     
    “Registrable Securities” shall mean the Shares and, to the extent applicable, any other shares of capital stock
or other securities of the Company or any successor to the Company that are issued upon exchange of such Shares.

 

(xii)        “Registration
Statement” shall mean a registration statement (a “Registration Statement”) relating to an offering for its own
account or the account of others under the 1933 Act of any of its equity securities, other than a shelf registration statement
or a registration statement on Form S-4 or Form S-8 (each as promulgated under the 1933 Act) or their then equivalents
relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities
issuable in connection with employee equity incentive plans.

 

(xiii)       “Securities”
means the Series F Shares, the Warrants and the Shares.

 

(xiv)       “Shares”
means the shares of Common Stock issuable upon conversion of the Series F Shares and the shares of Common Stock issuable upon
exercise of the Warrants.

 

(xv)        “Closing
Date” shall have the meaning ascribed to such term in Section 5(a).

 

(xvi)       “Subsidiary”
shall have the meaning ascribed to such term in Section 3(b).

 

    2

     

    

 

(xvii)      “Transaction
Documents” means, collectively, this Agreement, the Series F Shares and Designation, the Warrants, and the other agreements,
documents and instruments contemplated hereby or thereby.

 

(xviii)     “Transfer
Agent” shall have the meaning ascribed to such term in Section 4(a).

 

b.           Purchase
and Sale of Securities.

 

(i)          Subject
to the terms and conditions of this Agreement, and as set forth in Section 5 hereof, the Purchasers, severally and not jointly,
agree to purchase at the Closing and the Company agrees to issue and sell to the Purchasers the number of Units set forth opposite
each Purchaser’s name on the signature page hereto in exchange for the Purchase Price set forth thereon.

 

(ii)          To
subscribe, each Purchaser must send an executed copy of this Agreement and the Subscriber Questionnaire attached hereto as Exhibit C
to:

 

BioHiTech Global, Inc.

Attention: Brian C.
Essman, CFO

80 Red Schoolhouse
Road

Suite 101

Chestnut Ridge, New
York 10972 

Email: bessman@biohitech.com

 

along with, either

 

•               payment
of the Subscriber’s subscribed amount by wire transfer as follows:

 

Comerica Bank 

ABA No: 072000096 

SWIFT No: MNBDUS33 

 

For the benefit of: 

Account Name: BioHiTech
Global, Inc. 

Account No: 1853384210 

Memo: BHTG Units of
Sr F PS and Warrants

 

or

 

•              payment
of the Subscriber’s subscribed amount by check payable to “BioHiTech Global, Inc.”

 

2.           PURCHASER’S
REPRESENTATIONS, WARRANTIES, ETC.

 

The Purchaser represents
and warrants to, and covenants and agrees with, the Company as follows:

 

a.           Investment
Purpose. Without limiting the Purchaser’s right to sell the Securities, the Purchaser is purchasing the Securities,
and will be acquiring the Securities, for its own account for investment only and not with a view towards the public sale or distribution
thereof and not with a view to or for sale in connection with any distribution thereof.

 

b.          Accredited
Investor Status. Purchaser is (i) an “accredited investor” as that term is defined in Rule 501 of
the General Rules and Regulations under the 1933 Act by reason of Rule 501(a)(3), (ii) experienced in making investments
of the kind described in this Agreement and the related documents, (iii) able, by reason of the business and financial experience
of its officers (if an entity) and professional advisors (who are not affiliated with or compensated in any way by the Company
or any of its affiliates or selling agents), to protect its own interests in connection with the transactions described in this
Agreement, and the related documents, and (iv) able to afford the entire loss of its investment in the Securities; and has
completed the Subscriber Questionnaire attached hereto as Exhibit C.

 

    3

     

    

 

c.           Subsequent
Offers and Sales. All subsequent offers and sales of the Securities or Shares by the Purchaser shall be made pursuant
to registration of the Securities or Shares under the 1933 Act or pursuant to an exemption from registration and compliance with
applicable states’ securities laws.

 

d.           Reliance
on Exemptions. Purchaser understands that the Securities are being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying upon the
truth and accuracy of, and the Purchaser’s compliance with, the representations, warranties, agreements, acknowledgments
and understandings of the Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility
of the Purchaser to acquire the Securities.

 

e.           Information. Purchaser
and its advisors have been furnished with all materials relating to the business, finances and operations of the Company and materials
relating to the offer and sale of the Securities that have been requested by the Purchaser. Purchaser and its advisors have been
afforded the opportunity to ask questions of the Company and have received complete and satisfactory answers to any such inquiries.
Without limiting the generality of the foregoing, Purchaser has also had the opportunity to obtain and to review all of the Company’s
filings with the Securities and Exchange Commission, including, but limited to the Company’s Annual Report on Form 10-K
for the fiscal year ended December 31, 2018 and Quarterly Reports on Forms 10-Q and 10-Q/A (if applicable) for the fiscal
quarters ended March 31, 2019, June 30, 2019 and September 30, 2019, including the financial statements included
therein (the “SEC Documents”).

 

f.            Investment
Risk. Purchaser understands that its investment in the Securities involves a high degree of risk, including the risk of
loss of the Purchaser’s entire investment, and including, but not limited to the following: (a) the Company remains
an early stage business with limited operating history and requires substantial funds in addition to the proceeds of the Offering;
(b) an investment in the Company is highly speculative, and only investors who can afford the loss of their entire investment
should consider investing in the Company and the Units; (c) the Purchaser may not be able to liquidate its investment; (d) transferability
of the Securities is extremely limited; (e) in the event of a disposition, the Purchaser could sustain the loss of its entire
investment; (f) the Company has not paid any dividends on its Common Stock since its inception and does not anticipate paying
any dividends in the foreseeable future; and (g) the Company may issue additional securities in the future which have rights
and preferences that are senior to those of the Securities.

 

g.           Governmental
Review. Purchaser understands that no United States federal or state agency or any other government or governmental agency
has passed on or made any recommendation or endorsement of the Securities.

 

h.           Organization;
Authorization. If an entity, Purchaser is duly organized, validly existing and in good standing under the laws of the
jurisdiction of its organization. This Agreement and the other Transaction Documents have been duly and validly authorized, executed
and delivered on behalf of the Purchaser and create a valid and binding agreement of the Purchaser enforceable in accordance with
its terms, subject as to enforceability to general principles of equity and to bankruptcy, insolvency, moratorium and other similar
laws affecting the enforcement of creditors’ rights generally.

 

i.            Residency. The
state in which any offer to purchase shares hereunder was made to or accepted by Purchaser is the state shown as the Purchaser’s
address contained herein.

 

j.            Risk
Factors. The Company is in the early stage of its development and is therefore subject to risks and uncertainties. The occurrence
of any one or more of these risks and uncertainties could have a material adverse effect on the value of any investment in the
Company and the business, prospects, financial position, financial condition or operating results of the Company. Investors should
carefully consider these risk factors, together with all the other information about the Company available in its filings with
the Securities and Exchange Commission, which are hereby incorporated by reference.

 

    4

     

    

 

3.           COMPANY
REPRESENTATIONS AND WARRANTIES, ETC.

 

Except as set forth
in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or otherwise
made herein to the extent of the disclosure contained in the corresponding section of the Disclosure Schedules, the Company represents
and warrants to the Purchaser that:

 

a.           Concerning
the Securities. There are no preemptive rights of any stockholder of the Company to acquire the Securities which have
not been waived.

 

b.           Organization;
Subsidiaries; Reporting Company Status. The Company is a corporation duly organized, validly existing and in good standing
under the laws of the state of Delaware, and has the requisite corporate or other power to own its properties and to carry on its
business as now being conducted. The Company is duly qualified as a foreign corporation or other entity to do business and is in
good standing in each jurisdiction where the nature of the business conducted or property owned by it makes such qualification
necessary, other than those jurisdictions in which the failure to so qualify would not have a Material Adverse Effect. The Common
Stock is listed and traded on the Nasdaq Capital Market under symbol “BHTG”. The Company has received no notice, either
oral or written, from Nasdaq, the SEC, or any other organization, with respect to the continued eligibility of the Common Stock
for such listing, and the Company has maintained all requirements for the continuation of such listing.

 

c.           Authorized
Shares. The Company has sufficient authorized and unissued shares of Common Stock as may be necessary to effect the issuance
of the Securities, assuming the prior issuance and exercise, exchange or conversion, as the case may be, of all derivative securities
authorized. The Securities have been duly authorized and, when issued upon conversion or redemption of the Series F Shares
or upon exercise of the Warrants, the Shares will be duly and validly issued, fully paid and non-assessable and will not subject
the holder thereof to personal liability by reason of being such holder. At all times, the Company shall keep available and reserved
for issuance to the holders of the Securities, shares of Common Stock duly authorized for issuance against the Securities.

 

d.            Authorization. This
Agreement, the issuance of the Securities, the issuance of the Shares, and the other transactions contemplated by the Transaction
Documents, have been duly and validly authorized by the Company, and this Agreement has been duly executed and delivered by the
Company. Each of the Transaction Documents, when executed and delivered by the Company, are and will be, valid, legal and binding
agreements of the Company, enforceable in accordance with their respective terms, subject as to enforceability to general principles
of equity and to bankruptcy, insolvency, moratorium, and other similar laws affecting the enforcement of creditors’ rights
generally.

 

e.           Non-contravention. The
execution and delivery of the Transaction Documents, the issuance of the Securities and the consummation by the Company of the
other transactions contemplated by this Agreement and the issuance of Securities (including without limitation the incurrence of
indebtedness thereunder) do not and will not conflict with or result in a breach by the Company of any of the terms or provisions
of, or constitute a default under (i) the articles of incorporation or by-laws of the Company, each as currently in effect,
(ii) any indenture, mortgage, deed of trust, or other material agreement or instrument to which the Company is a party or
by which it or any of its properties or assets are bound, including any listing agreement for the Common Stock, except as herein
set forth or an event which results in the creation of any lien, charge or encumbrance upon any assets of the Company or the triggering
of any preemptive or anti-dilution rights or rights of first refusal or first offer on the part of holders of the Company’s
securities, (iii) to its knowledge, any existing applicable law, rule, or regulation or any applicable decree, judgment, or
order of any court, United States federal or state regulatory body, administrative agency, or other governmental body having jurisdiction
over the Company or any of its properties or assets, or (iv) the Company’s listing agreement for its Common Stock (if
applicable), except such conflict, breach or default which would not have a Material Adverse Effect.

 

f.            Approvals. No
authorization, approval or consent of any court, governmental body, regulatory agency, self-regulatory organization, or stock exchange
or market or the stockholders of the Company is required to be obtained by the Company for the entering into and performing this
Agreement and the other Transaction Documents (including without limitation the issuance and sale of the Securities to the Purchaser
as contemplated by this Agreement) except such authorizations, approvals and consents that have been obtained, or such authorizations,
approvals and consents, the failure of which to obtain would not have a Material Adverse Effect.

 

    5

     

    

 

g.           SEC
Filings; Rule 144 Status. None of the SEC Documents contained, at the time they were filed, any untrue statement
of a material fact or omitted to state any material fact required to be stated therein or necessary to make the statements made
therein in light of the circumstances under which they were made, not misleading. The Company is not aware of any event occurring
on or prior to the execution and delivery of this Agreement that would require the filing of, or with respect to which the Company
intends to file, a Form 8-K after such time.

 

h.           Absence
of Certain Changes. Since September 30, 2019, when viewed from the perspective of the Company and its Subsidiaries
taken as a whole, there has been no material adverse change and no material adverse development in the business, properties, operations,
condition (financial or otherwise), or results of operations of the Company and its Subsidiaries (including, without limitation,
a change or development which constitutes, or with the passage of time is reasonably likely to become, a Material Adverse Effect),
except as disclosed in the SEC Documents. Since September 30, 2019, except as provided in the SEC Documents, the Company has
not (i) incurred or become subject to any material liabilities (absolute or contingent) except liabilities incurred in the
ordinary course of business consistent with past practices; (ii) discharged or satisfied any material lien or encumbrance
or paid any material obligation or liability (absolute or contingent), other than current liabilities paid in the ordinary course
of business consistent with past practices; (iii) declared or made any payment or distribution of cash or other property to
stockholders with respect to its capital stock, or purchased or redeemed, or made any agreements to purchase or redeem, any shares
of its capital stock; (iv) sold, assigned or transferred any other tangible assets, or canceled any debts or claims, except
in the ordinary course of business consistent with past practices; (v) suffered any substantial losses or waived any rights
of material value, whether or not in the ordinary course of business, or suffered the loss of any material amount of existing business;
(vi) made any changes in employee compensation, except in the ordinary course of business consistent with past practices;
or (vii) experienced any material problems with labor or management in connection with the terms and conditions of their employment.

 

i.            Full
Disclosure. There is no fact known to the Company (other than general economic conditions known to the public generally
or as disclosed in the SEC Documents) that has not been disclosed in writing to the Purchaser that (i) would reasonably be
expected to have a Material Adverse Effect, (ii) would reasonably be expected to materially and adversely affect the ability
of the Company to perform its obligations pursuant to the Transaction Documents, or (iii) would reasonably be expected to
materially and adversely affect the value of the rights granted to the Purchaser in the Transaction Documents.

 

j.            Absence
of Litigation. Except as described in the SEC Documents, there is no action, suit, proceeding, inquiry or investigation
before or by any court, public board or body pending or, to the knowledge of the Company, threatened against or affecting the Company,
wherein an unfavorable decision, ruling or finding would have a Material Adverse Effect or which would adversely affect the validity
or enforceability of, or the authority or ability of the Company to perform its obligations under, any of the Transaction Documents.
The Company is not a party to or subject to the provisions of, any order, writ, injunction, judgment or decree of any court or
government agency or instrumentality which could reasonably be expected to have a Material Adverse Effect.

 

k.           Absence
of Events of Default. No Event of Default (or its equivalent term), as defined in the respective agreement, indenture,
mortgage, deed of trust or other instrument, to which the Company is a party, and no event which, with the giving of notice or
the passage of time or both, would become an Event of Default (or its equivalent term) (as so defined in such document), has occurred
and is continuing, which would have a Material Adverse Effect for which a waiver or forbearance agreement is not in effect.

 

l.            No
Undisclosed Liabilities or Events. The Company has no liabilities or obligations other than those disclosed in the SEC
Documents or those incurred in the ordinary course of the Company’s business since September 30, 2019, and which individually
or in the aggregate, do not or would not have a Material Adverse Effect. No event or circumstances has occurred or exists with
respect to the Company or its properties, business, condition (financial or otherwise), or results of operations, which, under
applicable law, rule or regulation, requires public disclosure or announcement prior to the date hereof by the Company but
which has not been so publicly announced or disclosed. There are no proposals currently under consideration or currently anticipated
to be under consideration by the Board of Directors or the executive officers of the Company which proposal would (x) change
the articles of incorporation, by-laws or any other charter document of the Company, each as currently in effect, with or without
shareholder approval, which change would reduce or otherwise adversely affect the rights and powers of the shareholders of the
Common Stock or (y) materially or substantially change the business, assets or capital of the Company.

 

    6

     

    

 

m.          No
Integrated Offering. Neither the Company nor any of its affiliates nor any Person acting on its or their behalf has, directly
or indirectly, at any time during the six month period immediately prior to the date of this Agreement made any offer or sales
of any security or solicited any offers to buy any security under circumstances that would eliminate the availability of the exemption
from registration under Rule 506 of Regulation D in connection with the offer and sale of the Securities as contemplated hereby.

 

n.           Regulatory Permits. The
Company has all such permits, easements, consents, licenses, franchises and other governmental and regulatory authorizations from
all appropriate federal, state, local or other public authorities (“Permits”) as are necessary to own and lease its
properties and conduct its businesses in all material respects in the manner described in the SEC Documents and as currently being
conducted. All such Permits are in full force and effect and the Company has fulfilled and performed all of its material obligations
with respect to such Permits, and no event has occurred that allows, or after notice or lapse of time would allow, revocation or
termination thereof or will result in any other material impairment of the rights of the holder of any such Permit, subject in
each case to such qualification as may be disclosed in the SEC Documents. Such Permits contain no restrictions that would materially
impair the ability of the Company to conduct businesses in the manner consistent with its past practices. The Company has not received
notice or otherwise has knowledge of any proceeding or action relating to the revocation or modification of any such Permit.

 

o.           Hazardous
Materials. The Company is in compliance with all applicable Environmental Laws in all respects except where the failure
to comply does not have and could not reasonably be expected to have a Material Adverse Effect. For purposes of the foregoing:

 

“Environmental
Laws” means, collectively, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended,
the Superfund Amendments and Reauthorization Act of 1986, the Resource Conservation and Recovery Act, the Toxic Substances Control
Act, as amended, the Clean Air Act, as amended, the Clean Water Act, as amended, any other “Superfund” or “Superlien”
law or any other applicable federal, state or local statute, law, ordinance, code, rule, regulation, order or decree regulating,
relating to, or imposing liability or standards of conduct concerning, the environment or any Hazardous Material.

 

“Hazardous Material”
means and includes any hazardous, toxic or dangerous waste, substance or material, the generation, handling, storage, disposal,
treatment or emission of which is subject to any Environmental Law.

 

4.            CERTAIN
COVENANTS AND ACKNOWLEDGMENTS.

 

a.           Transfer
Restrictions. The parties acknowledge and agree that (1) the Securities have not been registered under the provisions
of the 1933 Act and the Shares have not been registered under the 1933 Act, and may not be transferred unless (A) subsequently
registered thereunder or (B) sold or transferred pursuant to an exemption from such registration; (2) any sale of the
Securities made in reliance on Rule 144 promulgated under the 1933 Act (“Rule 144”) may be made only in accordance
with the terms of Rule 144 and further, if Rule 144 is not applicable, any resale of such Securities or Shares under
circumstances in which the seller, or the Person through whom the sale is made, may be deemed to be an underwriter, as that term
is used in the 1933 Act, may require compliance with some other exemption under the 1933 Act or the rules and regulations
of the SEC thereunder, (3) at the request of the Purchaser, the Company shall, from time to time, within two (2) business
days of such request, at the sole cost and expense of the Company, either (i) deliver to its transfer agent and registrar
for the Common Stock (the “Transfer Agent”) a written letter instructing and authorizing the Transfer Agent to process
transfers of the Shares at such time as the Purchaser has held the Securities for the minimum holding period permitted under Rule 144,
subject to the Purchaser’s providing to the Transfer Agent certain customary representations contemporaneously with any requested
transfer, or (ii) at the Purchaser’s option or if the Transfer Agent requires further confirmation of the availability
of an exemption from registration, furnish to the Purchaser an opinion of the Company’s counsel in favor of the Purchaser
(and, at the request of the Purchaser, any agent of the Purchaser, including but not limited to the Purchaser’s broker or
clearing firm) and the Transfer Agent, reasonably satisfactory in form, scope and substance to the Purchaser and the Transfer Agent,
to the effect that a contemporaneously requested transfer of shares does not require registration under the 1933 Act, pursuant
to the 1933 Act, Rule 144 or other regulations promulgated under the 1933 Act and (4) neither the Company nor any other
Person is under any obligation to register the Securities (other than pursuant to this Agreement) under the 1933 Act or to comply
with the terms and conditions of any exemption thereunder.

 

    7

     

    

 

b.           Restrictive
Legend. The Purchaser acknowledges and agrees that the Series F Shares, Warrants, and, until such time as the Shares
have been registered under the 1933 Act as contemplated hereby and sold in accordance with an effective Registration Statement,
certificates and other instruments representing any of the Securities or Shares shall bear a restrictive legend in substantially
the following form (and a stop-transfer order may be placed against transfer of any such Securities or Shares):

 

NEITHER THE ISSUANCE AND SALE
OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE [NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE] NOT BEEN
REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT
BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF
WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

c.           Piggy-back
Registration Rights. From and after the Closing Date and until six months thereafter, if there is not an effective registration
statement covering the resale all of the Registrable Securities, and Company shall determine to prepare and a Registration Statement
relating to an offering for its own account or the account of others under the 1933 Act, other than on Form S-4 or Form S-8
(each as promulgated under the 1933 Act), then Company shall send to the Purchaser a written notice of such determination and,
if within ten (10) days after receipt by Purchaser of such notice, the Company shall receive a request in writing from the
Purchaser, Company shall include in such registration statement all or any part of such Registrable Securities holders requests
to be registered at no cost to the Purchaser. Notwithstanding the foregoing, if a registration involves an underwritten offering,
and the lead managing underwriter shall advise Company that the amount of securities to be included in the offering exceeds the
amount which can be sold in the offering, the number of securities owned by Purchaser to be included in the offering shall be eliminated
or reduced as required by the managing underwriter. Notwithstanding anything contained herein to the contrary, securities shall
cease to be Registrable Securities when (a) a Registration Statement covering such Registrable Securities has been declared
effective by the Commission and it has been disposed of pursuant to such effective Registration Statement or (b) such Registrable
Securities may be sold pursuant to Rule 144 under the 1933 Act without volume restriction.

 

d.           Securities
Filings. The Company undertakes and agrees to make all necessary filings (including, without limitation, a Form D)
in connection with the sale of the Securities to the Purchaser required under any United States laws and regulations applicable
to the Company (including without limitation state “blue sky” laws), or by any domestic securities exchange or trading
market, and to provide a copy thereof to the Purchaser promptly after such filing.

 

    8

     

    

 

e.            Reporting
Status; Public Trading Market; DTC Eligibility. So long as the Purchaser beneficially owns any Series F Shares or
Warrants, (i) the Company shall timely file, prior to or on the date when due, all reports that would be required to be filed
with the SEC pursuant to Section 13 or 15(d) of the Exchange Act if the Company had securities registered under Section 12(b) or
12(g) of the Exchange Act; (ii) the Company shall not be operated as, or report, to the SEC or any other Person, that
the Company is a “shell company” or indicate to the contrary to the SEC or any other Person; (iii) the Company
shall take all other action under its control necessary to ensure the availability of Rule 144 under the 1933 Act for the
sale of Shares by the Purchaser at the earliest possible date; and (iv) the Company shall at all times while any Series F
Shares or Warrants are outstanding maintain its engagement of an independent registered public accounting firm. Except as otherwise
set forth in Transaction Documents, the Company shall take all action under its control necessary to obtain and to continue the
listing and trading of its Common Stock (including, without limitation, all Registrable Securities) on the Nasdaq Capital Markets.

 

f.            Roll-Over
Rights. (i)  From the Closing Date through twelve (12) months thereafter, upon any issuance by the Company or any of its
Subsidiaries, excluding registered offerings of the Company under the 1933 Act, of Common Stock or Common Stock Equivalents for
cash consideration, debt or a combination of units thereof (a “Subsequent Financing”), each Purchaser shall have the
right to participate in the Subsequent Financing by converting all, but not less than all of the Outstanding Balance of the Series F
Shares as the purchase price for the Subsequent Financing on the same terms, conditions and price provided for in the Subsequent
Financing.

 

(ii) Between the
time period of 4:00 pm (New York City time) and 6:00 pm (New York City time) on the Trading Day immediately prior to the Trading
Day of the expected announcement of the Subsequent Financing (or, if the Trading Day of the expected announcement of the Subsequent
Financing is the first Trading Day following a holiday or a weekend (including a holiday weekend), between the time period of 4:00
pm (New York City time) on the Trading Day immediately prior to such holiday or weekend and 2:00 pm (New York City time) on the
day immediately prior to the Trading Day of the expected announcement of the Subsequent Financing), the Company shall deliver to
each Purchaser a written notice of the Company’s intention to effect a Subsequent Financing (a “Subsequent Financing
Notice”), which notice shall describe in reasonable detail the proposed terms of such Subsequent Financing, the amount of
proceeds intended to be raised thereunder and the Person or Persons through or with whom such Subsequent Financing is proposed
to be effected and shall include a term sheet and transaction documents relating thereto as an attachment.

 

(iii) Any Purchaser
desiring to participate in such Subsequent Financing must provide written notice to the Company by 6:30 am (New York City time)
on the Trading Day following the date on which the Subsequent Financing Notice is delivered to such Purchaser (the “Notice
Termination Time”) that such Purchaser is willing to participate in the Subsequent Financing, the amount of such Purchaser’s
Outstanding Balance. If the Company receives no such notice from a Purchaser as of such Notice Termination Time, such Purchaser
shall be deemed to have notified the Company that it does not elect to participate in such Subsequent Financing.

 

(iv) If, by the
Notice Termination Time, notifications by the Purchasers of their willingness to participate in the Subsequent Financing (or to
cause their designees to participate) is, in the aggregate, less than the total amount of the Subsequent Financing, then the Company
may affect the remaining portion of such Subsequent Financing on the terms and with the Persons set forth in the Subsequent Financing
Notice.

 

(v) If, by the Notice
Termination Time, the Company receives responses to a Subsequent Financing Notice from Purchasers seeking to purchase more than
the aggregate amount of the Participation Maximum, each such Purchaser shall have the right to purchase its Pro Rata Portion (as
defined below) of the Participation Maximum. “Pro Rata Portion” means the ratio of (x) the Outstanding Balance
of a Purchaser participating under this Section 4(g) and (y) the sum of all the Outstanding Balances of all Purchasers
participating under this Section 4(g).

 

(vi) Notwithstanding
the foregoing, this Section 4(g) shall not apply in respect of an Exempt Issuance.

 

    9

     

    

 

5.           CLOSING.

 

a.           Closing.
Promptly upon the execution and delivery of this Agreement, the Series F Shares, and all conditions in Sections 6 and
7 herein are met (the “Initial Closing”), (A) the Company shall deliver to the Purchaser the following: (i) the
Series F Shares; (ii) the Warrants; and (ii) duly executed counterparts of the other Transaction Documents; and
(B) the Purchaser shall deliver to the Company the following: (i) the purchase price set forth on the signature page hereof
(the “Purchase Price”) and (ii) duly executed counterparts of the Transaction Documents (as applicable).

 

b.            Additional
Closings. The Company may issue additional Units pursuant to this Agreement to such Purchasers as it shall select, provided
that the amount of the Units issued pursuant to this Agreement does not exceed the Maximum Offering Amount, subject to the Company’s
right to increase the Offering Amount (each such issuance, a “Subsequent Closing” and together with the Initial Closing,
the “Closing” and the date of such Subsequent Closing, the “Subsequent Closing Date” and together with
the Initial Closing Date, the “Closing Date”). At each such Subsequent Closing, the Company will deliver to each of
the Purchasers the respective Series F Shares and the Warrants to be purchased by such Purchaser, against receipt by the Company
of the respective Purchase Price through the payment of cash as set forth on the signature page of such Agreement.

 

c.            Location
and Time of Closings. Each Closing shall be deemed to occur on the related Closing Date at the office of the Company’s
counsel and shall take place no later than 5:00 P.M., New York time, on such day or such other time as is mutually agreed upon
by the Company and the Purchaser.

 

6.           CONDITIONS
TO THE COMPANY’S OBLIGATION TO SELL.

 

The Company’s
obligation to sell the Series F Shares and Warrants to the Purchaser pursuant to this Agreement on each Closing Date is conditioned
upon:

 

a.           Purchase
Price. Delivery to the Company of good funds as payment in full of the Purchase Price for the Securities at the Closing
in accordance with this Agreement;

 

b.           Representations
and Warranties; Covenants. The accuracy on the Closing Date of the representations and warranties of the Purchaser contained
in this Agreement, each as if made on such date, and the performance by the Purchaser on or before such date of all covenants and
agreements of the Purchaser required to be performed on or before such date; and

 

c.           Laws
and Regulations; Consents and Approvals. There shall not be in effect any law, rule or regulation prohibiting or
restricting the transactions contemplated hereby, or requiring any consent or approval which shall not have been obtained.

 

7.           CONDITIONS
TO THE PURCHASER’S OBLIGATION TO PURCHASE.

 

The Purchaser’s
obligation to purchase the Series F Shares and Warrants at each Closing is conditioned upon:

 

a.           Transaction
Documents. The execution and delivery of this Agreement by the Company;

 

b.           Securities. Delivery
by the Company to the Purchaser of the Series F Shares and Warrants to be purchased in accordance with this Agreement;

 

c.           Section 4(2) Exemption. The
Series F Shares and Warrants sold pursuant to the Transaction Documents shall be exempt from registration under the 1933 Act,
pursuant to Section 4(2) thereof;

 

    10

     

    

 

d.           Representations
and Warranties; Covenants. The accuracy in all material respects on the Closing Date of the representations and warranties
of the Company contained in this Agreement, each as if made on such date, and the performance by the Company on or before such
date of all covenants and agreements of the Company required to be performed on or before such date;

 

8.           GOVERNING
LAW; MISCELLANEOUS.

 

a.           Governing
Law. This Agreement shall be delivered and accepted in and shall be deemed to be contracts made under and governed by
the internal laws of the State of New York, and for all purposes shall be construed in accordance with the laws of the State of
New York, without giving effect to the choice of law provisions.

 

b.           Waivers. Failure
of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or
remedy, shall not operate as a waiver thereof.

 

c.           Successors
and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and assigns of each of the
parties hereto.

 

d.           Construction. All
pronouns and any variations thereof refer to the masculine, feminine or neuter, singular or plural, as the context may require.

 

e.            Facsimiles;
E-mails. A facsimile or email transmission of this signed Agreement or a Notice of Conversion under the Series F
Shares or Notice of Exercise under the Warrants shall be legal and binding on all parties hereto. Such electronic signatures shall
be the equivalent of original signatures.

 

f.            Counterparts. This
Agreement may be signed in one or more counterparts, each of which shall be deemed an original.

 

g.           Headings. The
headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.

 

h.           Enforceability. If
any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall
not affect the validity or enforceability of the remainder of this Agreement or the validity or enforceability of this Agreement
in any other jurisdiction.

 

i.            Amendment. This
Agreement may be amended only by the written consent of a majority in interest of the holders of the Debentures and an instrument
in writing signed by the Company.

 

j.             Entire Agreement. This Agreement, together with the other Transaction
Documents, supersedes all prior agreements and understandings among the parties hereto with respect to the subject matter
hereof.

 

k.           No
Strict Construction. This Agreement shall be construed as if both Parties had equal say in its drafting, and thus shall
not be construed against the drafter.

 

l.            Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and
shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

 

9.           NOTICES.

 

Any notice required
or permitted hereunder shall be given in writing (unless otherwise specified herein) and shall be deemed effectively given on the
earliest of:

 

    11

     

    

 

a.           the
date delivered, if delivered by personal delivery as against written receipt therefor or by confirmed facsimile transmission,

 

b.           the
seventh business day after deposit, postage prepaid, in the United States Postal Service by registered or certified mail, or

 

c.           the
third business day after mailing by next-day express courier, with delivery costs and fees prepaid, in each case, addressed to
each of the other parties thereunto entitled at the following addresses (or at such other addresses as such party may designate
by ten (10) days’ advance written notice similarly given to each of the other parties hereto):

 

COMPANY:               BioHiTech
Global, Inc.

         80 Red Schoolhouse Road, Suite 101

         Chestnut Ridge, NY 10977

         Attention: Frank E. Celli and
Brian C. Essman

         Email: fcelli@biohitech.com
and bessman@biohitech.com

 

	 	With copies to (which shall not constitute notice):
	 	  McCarter & English, LLP
	 	  Two Tower Center Boulevard, 24th Floor
	 	  East Brunswick, NJ 08816
	 	  Attention: Peter Camoitiello
	 	  Email: pcampitiello@mccarter.com
	 	 
	PURCHASER:	 
	 	 
	 	To the address set forth on the signature page hereof.

 

[Signature Page Follows]

 

    12

     

    

 

IN
WITNESS WHEREOF, THE UNDERSIGNED HAS EXECUTED THIS SECURITIES PURCHASE

AGREEMENT ON THE DATE SET FORTH BELOW.

 

The undersigned is subscribing for Series F
Shares at the purchase price of $115 per Share for an aggregate investment of $_______________.

 

The Shares(s) is/are
to be issued in the name of (check one box):

 

	 	____	individual name

	 	____	joint tenants with rights of survivorship

	 	____	tenants in the entirety

	 	____	corporation (an officer must sign)
	 	____	Partnership (all general partners must sign)

 

	
         

        Date:
	 	 	 
	 	 	 	 
	Print Name of Investor:	 	 	 
	
         

        Signature of Investor:
	 	 	 
	 	(and title if signing on behalf of an entity)

 

	Print Name of Joint Investor:	 	 
	 	 	 
	Signature of Joint Investor:	 	 
	 	 	 
	Address of Investor:	 	 
	 	 	 
	 	 	 
	 	 	 
	Social Security Number (if individual):	 	 	 
	 	 	 	 
	Tax Identification Number (if entity):	 	 	 
	 	 	 	 
	State of Organization (if entity):	 	 	 

 

	AGREED TO AND ACCEPTED:
	 
	As of ___________ __, 2020
	 
	BIOHITECH GLOBAL, INC.

                     

	By:	 	       
	 	Name:
	 	Title:

 

    13Exhibit 10.2

 

THIS WARRANT AND THE SECURITIES ISSUABLE
UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES
LAWS OF ANY STATE. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF
A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO SUCH SECURITIES UNDER SUCH ACT AND QUALIFICATION UNDER APPLICABLE STATE SECURITIES
LAWS, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION AND QUALIFICATION IS NOT REQUIRED.

 

BIOHITECH GLOBAL, INC.

 

COMMON STOCK PURCHASE WARRANT

 

	Warrant Shares: _________	Issue Date:  March __, 2020

 

THIS COMMON STOCK PURCHASE
WARRANT (the “Warrant”) certifies that, for value received, [______________] or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time after
date that is six (6) months following the Issue Date set forth above (the “Initial Exercise Date”)
and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination
Date”) but not thereafter, to subscribe for and purchase from BioHiTech Global, Inc., a Delaware corporation
(the “Company”), up to [_______] shares (as subject to adjustment hereunder, the “Warrant
Shares”) of Common Stock, par value $0.0001 per share (the “Common Stock”). The purchase price of one
share of Common Stock under this Warrant shall be equal to the Exercise Price, as set forth below. This Warrant is issued pursuant
to a Securities Purchase Agreement of even date herewith (the “Purchase Agreement”), and any capitalized
term used herein, and not otherwise defined, shall have the meaning ascribed thereto in the Purchase Agreement.

 

The following is a statement of the rights
of the Holder of this Warrant and the conditions to which this Warrant is subject, to which the Holder, by the acceptance of this
Warrant, agrees:

 

1.            Certain
Definitions.

 

1.1         “Exercise
Price” means [the greater of: $2.30 per share; or the closing Bid Price of the Common Stock on the Trading Day immediately
prior to the Issue Date.

 

1.2         “Expiration
Date” means the date that is five (5) years after the issue date set forth above.

 

1.3         “Shares”
or “Warrant Shares” means the shares of Common Stock issuable under this Warrant, as set forth above.

 

1.4         “Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading
on the date in question: the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, the NYSE American, OTCQB or OTCQX (or any successors to any of the foregoing).

 

2.            Number
of Shares and Exercise.

 

2.1         This
Warrant shall be exercisable for such number of Warrant Shares as set forth above, at the Exercise Price.

 

    1

     

    

 

2.2         This
Warrant may be exercised in whole or in part at any time beginning on the date on which the Initial Exercise Date and continuing
thereafter and from time to time on or prior to the Expiration Date.

 

3.            Exercise
of Warrant

 

3.1         The
purchase rights represented by this Warrant are exercisable by the Holder, in whole or in part, by the surrender of this Warrant
and the Notice of Exercise annexed hereto duly executed at the Company’s principal executive office (or such other office
or agent of the Company as it may designate by notice in writing to the Holder at the address of the Holder appearing on the books
of the Company), and upon payment of the aggregate Exercise Price of the Shares thereby purchased (by check or bank draft payable
to the order of the Company); whereupon the Holder shall be entitled to receive the number of Shares so purchased. The Company
agrees that if at the time of the surrender of this Warrant and purchase of the Shares, the Holder shall be entitled to exercise
this Warrant, the Shares so purchased shall be issued to the Holder as the record owner of such Shares as of the close of business
on the date on which this Warrant shall have been exercised as aforesaid or on such later date requested by the Holder or on such
earlier date agreed to by the Holder and the Company.

 

3.2         Delivery
of Common Stock Certificates and New Warrant. As soon as reasonably practicable after each exercise of this Warrant, in
whole or in part, and in any event within five (5) business days thereafter (the “Warrant Share Delivery Date”),
the Company, at its expense (including the payment by it of any applicable issue taxes), will cause the name of the Holder (or
as Holder may direct) to be entered in the register of holders in respect of the Warrant Shares and further cause to be issued
in the name of and delivered to the Holder hereof or as the Holder (upon payment by the Holder of any applicable transfer taxes)
may direct:

 

(a)         the
number of duly authorized, validly issued, fully paid and nonassessable Warrant Shares to which the Holder shall be entitled upon
exercise, in certificated form with appropriate restrictive legends, if applicable; and

 

(b)         in
case exercise is in part only, a new Warrant document of like tenor, dated the date hereof, for the remaining number of Warrant
Shares issuable upon exercise of this Warrant after giving effect to the partial exercise of this Warrant (including the delivery
of any Warrant Shares as payment of the Exercise Price for such partial exercise of this Warrant).

 

3.3         Cashless
Exercise. If, but only if, at the time of exercise hereof there is no effective registration statement registering, or the
prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may be exercised,
in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive
a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

(A) =
as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such
Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading
Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of
 “regular trading hours” (as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities
laws) on such Trading Day, (ii) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg
L.P. as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed
during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter pursuant to Section 2(a) hereof
or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day
and such Notice of Exercise is both executed and delivered pursuant to Section 1(a) hereof after the close of “regular
trading hours” on such Trading Day;

 

    2

     

    

 

(B) =
the Exercise Price of this Warrant, as adjusted hereunder; and

 

(X) =
the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
if such exercise were by means of a cash exercise rather than a cashless exercise.

 

“Bid
Price” means, for any date, the price determined by the following: (a) if the Common Stock is then listed or quoted
on a Trading Market, the bid price of the Common Stock during the two (2) hours prior to the delivery of the applicable Notice
of Exercise, as such bid price is selected by the Holder, on the Trading Market on which the Common Stock is then listed or quoted
as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City
time)) or (b) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable
to the Company, the fees and expenses of which shall be paid by the Company.

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on
a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not
a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB
or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for
the Common Stock are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.

 

4.            Nonassessable.
The Company covenants that all Shares which may be issued upon the exercise of this Warrant will be validly issued, fully paid
and nonassessable and free from all taxes, liens and charges in respect of the issue thereof.

 

5.            Fractional
Shares. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.
With respect to any fraction of a share called for upon the exercise of this Warrant, the number of shares delivered shall be rounded
up to the nearest whole share.

 

6.            Charges,
Taxes and Expenses. Issuance of Shares upon the exercise of this Warrant, in certificated form or otherwise, shall be made
without charge to the Holder hereof for any issue or transfer tax or other incidental expense in respect of the issuance, including
relating to any certificate, all of which taxes and expenses shall be paid by the Company, and such Shares shall be issued in the
name of the Holder.

 

7.            No
Rights as Shareholders. This Warrant does not entitle the Holder to any voting rights or other rights as a shareholder
of the Company prior to the exercise hereof.

 

8.             Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall be a Saturday, a Sunday or a legal holiday, then such action may be taken or such right may be
exercised on the next succeeding day that is not a Saturday, Sunday or legal holiday.

 

    3

     

    

 

9.             Adjustments.
The Exercise Price and the number of Shares purchasable hereunder are subject to adjustment from time to time as set forth
in this Section 9.

 

9.1         Reclassification, etc. If
the Company, at any time while this Warrant, or any portion thereof, remains outstanding and unexpired, by reclassification of
securities or otherwise, shall change the class of the securities as to which purchase rights under this Warrant exist into the
same or a different number of securities or any other class or classes of securities, this Warrant shall thereafter represent the
right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the
securities that were subject to the purchase rights under this Warrant immediately prior to such reclassification or other change
and the Exercise Price therefor shall be appropriately adjusted, all subject to further adjustment as provided in this Section 9.

 

9.2         Subdivision
or Combination of Shares. In the event the Company shall at any time subdivide the outstanding securities as to which
purchase rights under this Warrant exist, or shall issue a stock dividend on the securities as to which purchase rights under this
Warrant exist, the number of securities as to which purchase rights under this Warrant exist immediately prior to such subdivision
or to the issuance of such stock dividend shall be proportionately increased, and the Exercise Price shall be proportionately decreased,
and in the event that the Company shall at any time combine the outstanding securities as to which purchase rights under this Warrant
exist, the number of securities as to which purchase rights under this Warrant exist immediately prior to such combination shall
be proportionately decreased, and the Exercise Price shall be proportionately increased, effective at the close of business on
the date of such subdivision, stock dividend or combination, as the case may be.

 

9.3         Adjustment
upon Issuance of Common Stock or Common Stock Equivalents. If at any time on or after the Initial Exercise Date the Company
issues or sells, or in accordance with this is deemed to have issued or sold, any warrants to purchase shares of Common Stock or
Common Stock Equivalents at an exercise price (the “New Issuance Price”) less than a price (the “Applicable Price”)
equal to the Exercise Price in effect immediately prior to such issue or sale or deemed issuance or sale (the foregoing, a “Dilutive
Issuance”), then immediately after such Dilutive Issuance the Exercise Price then in effect shall be reduced to an amount
equal to the New Issuance Price. For the purposes of this Section 9.3, “Common Stock Equivalents” means any securities
of the Company which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt,
preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable
for, or otherwise entitles the holder thereof to receive, Common Stock, excluding those issued under employee stock compensation
plans.

 

9.4         Cash
Distributions. No adjustment on account of cash dividends or interest on the securities as to which purchase rights under
this Warrant exist will be made to the Exercise Price under this Warrant.

 

10.          Miscellaneous.

 

10.1       Loss,
Theft, Destruction or Mutilation of Warrant. Upon receipt of evidence reasonably satisfactory to the Company of the loss,
theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, delivery of an indemnity agreement
reasonably satisfactory in form and substance to the Company or, in the case of mutilation, on surrender and cancellation of this
Warrant, the Company shall execute and deliver, in lieu of this Warrant, a new Warrant executed in the same manner as this Warrant
and of like tenor and amount.

 

10.2       Waivers
and Amendments. This Warrant and the obligations of the Company and the rights of the Holder under this Warrant may be
amended, waived, discharged or terminated (either generally or in a particular instance, either retroactively or prospectively
and either for a specified period of time or indefinitely) with the written consent of the Company (which shall not be required
in connection with a waiver of rights in favor of the Company) and the holders of at least a majority of the then-outstanding holders
of shares of the Company’s Series F Redeemable, Convertible Preferred Stock (the “Series F Shares”); provided, however,
that no such amendment or waiver shall reduce the number of Shares represented by this Warrant without the consent of the Holder
hereof; and provided further, however, that nothing shall prevent the Holder from individually agreeing to waive the
observation of any term of this Warrant. Any amendment, waiver, discharge or termination effected in accordance with this Section 10.2
shall be binding upon the Company, the Holder, and except pursuant to a waiver by an individual holder of another Warrant pursuant
to the final proviso in the immediately preceding sentence, each other holder of Warrants.

 

    4

     

    

 

10.3       Notices. Any
notice, request or other communication required or permitted hereunder shall be given in accordance with the Purchase Agreement.

 

10.4       Severability. If
one or more provisions of this Warrant are held to be unenforceable under applicable law, such provision(s) shall be excluded
from this Warrant and the balance of this Warrant shall be interpreted as if such provision(s) were so excluded and shall
be enforceable in accordance with its terms.

 

10.5       Successors
and Assigns. Neither this Warrant nor any rights hereunder are transferable without the prior written consent of
the Company. Notwithstanding the foregoing, the Holder shall be permitted to transfer this Warrant to any affiliate (as that term
is defined in the Securities Act of 1933, as amended) of the Holder. If a transfer is permitted pursuant to this Section, the transfer
shall be recorded on the books of the Company upon the surrender of this Warrant, properly endorsed, to the Company at its principal
offices, and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. In the event
of a partial transfer, the Company shall issue to the holders one or more appropriate new warrants. Subject to the foregoing, the
provisions of this Warrant shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators
of the Company and the Holder.

 

10.6       Delays
or Omissions. No delay or omission to exercise any right, power, or remedy accruing to the Holder, upon any breach or
default of the Company under this Warrant shall impair any such right, power, or remedy of the Holder nor shall it be construed
to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter
occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default therefore or
thereafter occurring. Any waiver, permit, consent, or approval of any kind or character on the part of the Holder of any breach
or default under this Warrant or any waiver on the part of the Holder of any provisions or conditions of this Warrant must be made
in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Warrant
or by law or otherwise afforded to the Holder, shall be cumulative and not alternative.

 

10.7       Titles
and Subtitles. The titles of the paragraphs and subparagraphs of this Warrant are for convenience of reference only and
are not to be considered in construing this Warrant.

 

10.8       Construction. The
language used in this Warrant will be deemed to be the language chosen by the parties to express their mutual intent and no rules of
strict construction will be applied against any party.

 

10.9       Governing
Law. THIS WARRANT SHALL BE GOVERNED IN ALL RESPECTS BY THE LAWS OF THE STATE OF NEW YORK AS SUCH LAWS ARE APPLIED TO AGREEMENTS
BETWEEN NEW YORK RESIDENTS ENTERED INTO AND TO BE PERFORMED ENTIRELY WITHIN NEW YORK.

 

[Remainder of page intentionally
left blank]

 

    5

     

    

 

IN WITNESS WHEREOF,
BioHiTech Global, Inc. has caused this Warrant to be executed by its officer thereunto duly authorized.

 

 

	BIOHITECH GLOBAL, INC.	 
	 	 
	 	 
	By:	 	 
	      	Name:	 
	      	Title:	 

 

    6

     

    

 

NOTICE OF EXERCISE

 

	TO:	BioHiTech Global, Inc.
	 	80 Red Schoolhouse Road, Suite 101
	 	Chestnut Ridge, NY 10977
	 	Attn: Secretary

 

The undersigned hereby elects to purchase _______ shares (the
 “Shares”) of the Common Stock of BioHiTech Global, Inc. pursuant to the terms of the attached Warrant
and tenders herewith payment of the purchase price in full.

 

Please issue the Shares, including in certificated form with
appropriate restrictive legends, if applicable, in the name of the undersigned or in such other name as is specified below:

 

	 	 
	(Print Name)	 
	 	 
	Address:	 	 
	 		 
	 	 

 

The undersigned confirms that the undersigned
is an “accredited investor” within the meaning of Rule 501 of Regulation D under the Securities Act of 1933, as
amended, and that the Shares are being acquired for the account of the undersigned for investment only and not with a view to,
or for resale in connection with, the distribution thereof, and that the undersigned has no present intention of distributing or
selling the Shares.

 

	 	 	 
	(Date)	 	(Signature)
	 	 	 
	 	 	 
	(Print Name)	 	 

 

    7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]